MediTox s.r.o. is a **GLP-certified CRO** having experience in variety of compounds and therapeutic areas, with an experts and associates teams capable to conduct a number of experiments in full compliance with GLP standards and in compliance with another international guidelines **(EMA/ICH, VICH, OECD, US FDA, ISO10993).**

Certification
GLP Certificate (OECD GLP [C(97)186 Final])
Authorization for the Breeding and Use of Laboratory Animals (Ministry of Agriculture)
OLAW Welfare Approval (National Institute of Health, Office of Laboratory Animal Welfare, USA)
Authorization for GMO handling (in compliance with Act No. 153/2000 Coll
Crédit Impôt Recherche (CIR) accreditation (French Ministry of High Education, Research and Innovation)

The capabilities cover core range of non-clinical tests/studies providing the substantial information on the leads to support **phases I - III of** clinical trials and/or registration of **human drugs** and clinical trials/registration of **veterinary drugs.**
General and specific routes of administration in all common laboratory species, conventional/SPF/BSL II housing conditions are available. The toxicologists have experience with variety of compounds and therapeutic areas. The team is especially strong in **non-rodent** experiments, particularly ferret**, rabbit, cat and dog models**. The substantial advantage is long experience and expertise in **non-rodent toxicology.**

Summary product/service/technologies
Single and repeated dose studies in rodent and non-rodent species, genetic toxicology, safety pharmacology (CNS, CVS, respiratory), preclinical assessment of vaccines, biotech-derived drugs, PK/TK/BA studies, target animal safety and BEQ studies, safety assessment of food/feed additives, biocompatibility of medical devices and animal models of selected human diseases.

Quality
MediTox s.r.o. strictly adheres to comprehensive quality assurance program covering every aspect of the activities from business negotiations through material supply, personal training, data management and reporting.

Main activities:

- **Preclinical development** in area of vaccines, ophthalmic diseases, osteoarthrosis
- **Comprehensive preclinical, toxicology and safety program** for assessment of **human/veterinary drugs** (small molecules, vaccines, biotech-derived), food/feed additives, medical device **(ISO 10993**), chemicals, and agrochemicals
- **Animal models of selected human diseases** (chronic glaucoma, osteoarthritis, influenza, contact dermatitis)
- **Breeding of laboratory animals** (beagle dogs)

MediTox R&D activities within advanced projects (in the cooperation of the Czech and foreign research institutions and universities) are pointed to the area of anti-influenza and other anti-viral vaccines, ophthalmic diseases and regenerative medicine.
Essential activity is participation in EU grants projects, by this time we participated in more than 15 EU grant projects.

References

AlzProtect (FR), Beznoska (CZ), CHR. Hansen (DK), Contipro (CZ), Domes Pharma (FR), FATRO (IT), Herantis (FI), HUVE Pharma (BE), KRKA (SLO), Lasak (CZ), Lesaffre (FR), Mount Sinai School of Medicine (USA), Polphaema (PL), VetBiobank (FR), Virbac (FR) …

Company highlights
Animal models of selected human diseases (chronic glaucoma in dogs, influenza in ferrets, contact dermatitis in pigs, osteoarthrosis in dogs, wound healing in rats and pigs
Strong expertize in non-rodent toxicology (rabbits, cats, ferrets, dogs, pigs/minipigs, non-human primates)
Expertize in veterinary surgery (subcutis, muscle, bone implantation)

Expected highlights
Chronic glaucoma in rabbits, osteoarthritis in rabbits, periodontal disease model dogs

600 znaků

MediTox is a **GLP-certified CRO** having experience in variety of compounds and therapeutic areas, with an experts and associates teams capable to conduct a number of experiments and studies in full compliance with GLP standards and with another international guidelines **(EMA/ICH, VICH, OECD, US FDA, ISO10993), providing** core range of nonclinical studies supporting **phases I - III of** clinical trials and/or registration of **human drugs, medical device and food additives and safety/BEQ/efficacy studies for registration of veterinary drugs and feed additives.**

Summary of products/services
- MTD, DRF, pilot, proof-of-concept studies (rodents, non-rodents)
- Acute, sub-acute, subchronic, chronic toxicity studies (OECD, ICH/VICH, EFSA, rodents, - non-rodents)
- Medical device biocompatibility including implantation (ISO 10993, rodents, non-rodents)
- Genetic tox studies (OECD, ICH, ISO 10993. in vitro, in vivo)
- BA/BEQ/TK studies (OECD, ICHS, VICH, rodents, non-rodents)
- TAS, BEQ studies (VICH, dogs, cats, rabbits)
- Local effect (ICH, OECD, ISO 10993, Irritation, sensitization, local tolerance)
- Non-clinical safety, safety pharmacology (ICH)
- Medical device biocompatibility (ISO 10993, rodents, non-rodents)
- Feed and feed additives testing (EFSA, rodents, non-rodents)
- Experimental models available: chronic glaucoma (dog), arthrosis (dog)

Partnering strategy
Meeting potential clients and partners, gathering new information from the area, seeking new business and scientific collaborations, offering targeted and high-quality professional services, a strictly individual approach to solutions and competitive prices.

Selection of Client portfolio

AlzProtect (FR), Beznoska (CZ), CHR. Hansen (DK), Contipro (CZ), Domes Pharma (FR), FATRO (IT), Herantis (FI), HUVE Pharma (BE), KRKA (SLO), Lasak (CZ), Lesaffre (FR), Mount Sinai School of Medicine (USA), Polpharma (PL), VetBiobank (FR), Virbac (FR) …